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Personal Reflection – João Malheiro (26169)
4
BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care
Hard Skills
Data Gathering, Structuring and Analysis: Researched and collected data from several reliable
databases and websites, analyzing, and displaying data in a understandable way.
Which har /sof  skills did y u develop through the project?1
Soft Skills
PE industry knowledge: Got in touch with several concepts, content, and real cases related with the
PE sector which have helped me deepening my interest in this industry.
Financial Modeling: Excel financial modelling was key in this WP and it has helped me improve my
skills in this field.
Communication Skills: Improved my English speaking and writing capabilities.
Time management Skills: Given the long period of time dedicated to this WP, these skills were
essential not to lose focus on the important topics.
TeamWork Skills:Worked in a multi-cultural team with different working methods which contributed to
improve my adaptability to different working environments.
What would you change in your individual or team approach if you had to do a similar project?2
Individual Approach Team Approach
Given the vast available time to complete the WP, in some cases I have postponed tasks which I could
have completed earlier. This would be something to improve at in a similar project.
Sometimes I felt that the team was overdoing some tasks which did not add that much value. Would 
have been better to prioritize other tasks.
General
Opportunity to meet and discus theWP with well prepared advisors.
What skills did the Masters’ program gave you so you could be prepared for this kind of project?3
Private Equity Course
Time Management and Interpersonal Skills.
Vast and deep knowledge on the PE industry’s key concepts and investment approaches.
Opportunity to develop a similar project to the PE Challenge Field Lab WP, which was helpful given the
feedback provided.









EV/EBITDA LTM 5yr Average
EV/EBITDA Median Through The
Cycle (TTC)
Regression EV/EBITDA vs. Revenue
CAGR
Valuation
The valuation of BioTel suggests an EV/EBITDA multiple of 12.7x resulting in an Enterprise Value 
of approximately $1,292mn considering the company’s 2019 EBITDA of $102mn



























Notes: 1See Appendix 28-32. Sources: MergerMarket; Bloomberg; CapitalIQ
• By testing the sensitivity ofWACC and TV growth, DCF recommends an EV/EBITDA-range
of 9.8x to 14.2x and a median EV/EBITDA multiple of 11.6x.
• Adjusting for CAPEX, the EV/(EBITDA-CAPEX) multiple increases to 19.2x. Due to the
conventionality of high CAPEX requirements in the industry, this effect is neglected.
• Accounting for a risk adjustment of 1.5% due to the reimbursement risk and the high growth















• Precedent transactions recommend an EV/EBITDA multiple of 12.9x.
• Transactions occurred in the Medical Equipment and Diagnostic Services between the
years 2010 to 2013.
• Most targets were headquartered in the US, with one exception (Australia), where only the
bidder is from the US.










es • Trading comparables recommend an EV/EBITDA multiple between 12.4x and 18.5x.
• Trading comparables analyzed are listed US-based Medical Equipment manufacturers
and Diagnostic Services providers.
• Comparables’ 2018 EBITDA margins range from 17-22%, while BioTel achieved 23%.
• TTC EV/EBITDA LTM analysis was performed using the trading comparables previously
identified. The cycle term was set as 10 years.











y • Considering implied and relative valuation methods, including precedent transactions as well
as current and historical trading comparables, BioTel can be valued at an EV/EBITDA
multiple of 12.7x (i.e. the median of all valuation methods).










EV/EBITDA LTM (10Y Average)
Trading Comparables
EV/EBITDA Through he Cycle (TTC)
r ssio  Analysis
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Capital Structure – Overview
The acquisition will be levered with 6.0x Total Debt, whereof 5.0x are Senior Bank Debt and 1.0x 
will be raised as PIK Loan
Debt Source
• Senior and secured.
• Tenor: 7 years.











Notes: 1See Appendix 33; 2Debt sponsors provide Senior Secured Debt reflecting up to 3.0x Interest Cover based on EBITDA at acquisition. Hence, BioTel can afford ~$34mn of Cash Interest or ~518mn Senior Secured Debt considering its $102mn
EBITDA and 6.5% interest; 3Cash Available for Optional Debt Repayments = Total Cash Available for Debt Repayments – Total Mandatory Debt Repayments; 4See Appendix 34. Sources: Invesco Call; Team Assessment
Maturity and Spreads1 Repayment Schedule
Term Loan B
(3.0x EBITDA)2
• Increasing mandatory annual repayments.
• Additional leverage in 2021 to initial 2.0x




• Senior and secured.
• Tenor: 8 years.
• 450bps + 5Y Libor Swap Rate.
• Subordinated.
• Tenor: 10 years.
• 850bps + 5Y Libor Swap Rate.
• No mandatory annual repayments.
• Optional repayment if CODR3 > 0.
• Bullet repayment of outstanding debt in
year 8.
• Non-cash interest payments and no-call
protection covenants.
• Bullet repayment of principal and total
accrued interests in year 10.




• Tenor of 10 years and accrued interest rate of 10%.










• MEP investment in Ordinary Equity will grant the participants in the MEP the
remaining 20% of total shares.
• Upper Management4: Co-investors include CEO, CFO, CMO, and SVPs.
Upfront investment amounts to 2x annual salary.
• Sales Force: Alignment of incentives with essential sales force.
Uses of Funds Breakdown, In $mn
Uses of Funds
$mn % EBITDAx $mn % EBITDAx 
Senior Debt 508.8 37.4% 5.0x EBITDA in 2019B 101.8
Term Loan A 203.5 14.6% 2.0x EV/EBITDA 12.7x
Term Loan B 305.3 21.9% 3.0x
Subordinated Debt 101.8 7.3% 1.0x Total Equity 1,163.5 83.3% 11.4x
PIK Loan 101.8 7.3% 1.0x Debt Repayment 213.4 15.3% 2.1x
Total Debt 610.5 43.7% 6.0x Equity + Debt 1,376.9 98.6% 13.5x
FRI 563.4 40.3% 5.5x
Ordinary Equity 104.5 7.5% 1.0x
Institutional Equity 83.6 0.8x Transaction Fees 11.6 0.8% 0.1x
MEP 20.9 0.2x Financing Fees 7.8 0.6% 0.1x
Total Equity 667.8 47.8% 6.6x Total Fees 19.4 1.4% 0.2x
Cash on Hand 117.9 8.4% 1.2x
Total Sources 1,396.3 100% 13.7x Total Uses 1,396.3 100% 13.7x
RCF
($30mn)
• 200bps + 5Y Libor Swap Rate.
• 25bps flat commitment fee.
• The RCF is not expected to be drawn
down during the investment period.
• Annual payment of commitment fee.









Capital Structure – Deleveraging & Credit Statistics
Forecasted debt deleveraging and repayment schedule allow BioTel to respect the proposed 
financial covenants during the investment period
204 198


















At Entry 2020E 2021E 2022E 2023E 2024E 2025E
Term A Term B PIK Loan Bank Loans
Deleveraging & Debt Ending Balances, In $mn
Debt Repayment & Releveraging Schedule, In $mn
Credit Statistics




1 (34.7) (69.4) (69.4) (86.8)
Interest Expense (11.1) (15.1) (18.3) (15.4) (11.5) (7.2)
Term B
Optional Repayments (15.5) (106.5) (40.3) (33.6) (18.5) (57.6)
Interest Expense (18.0) (14.3) (9.9) (7.6) (6.0) (3.8)
PIK Loan
Accrued Interests 10.2 11.2 12.4 13.6 15.0 16.5
Total Debt Repayments (20.6) 42.2 (75.0) (103.0) (87.9) (144.4)
Total Cash Interest Expense (29.1) (29.4) (28.1) (23.0) (17.6) (10.9)
• Leverage Cover ratio is given by Net Debt over EBITDA.
• CAPEX Adjusted Leverage Coverage ratio is given by Net Debt over
EBITDA net of CAPEX (excluding SHL Telemedicine acquisition).
• High cash generation business model, which allows for optional debt
repayments, leads to a decrease in the leverage cover ratio overtime.
Leverage Cover
• Interest Cover ratio is given by EBITDA over Total Cash Interest
Expenses.
• CAPEX Adjusted Leverage Coverage ratio is given by EBITDA net of
CAPEX (excluding SHL Acquisition) over Total Cash Interest Expenses.
• Debt repayment and strong EBITDA growth lead to ratio improvement.
Interest Cover
• Cash Cover ratio is given by Unlevered FCF over Total Debt Service
(Total Interest Expenses and Total Mandatory Repayments).
• Cash Cover ratio forecast shows that BioTel has a strong cash
generation to meet its financial obligations during the investment period.
• Increase in 2021’s ratio is due to the re-leveraging of Term Loan A.
Cash Cover1Releveraging of Term A Loan to 2.0x 2021 EBITDA. Total effective releveraging amount is $148.7mn and it
will be used to finance the acquisition of SHL in 2021 and to repay more expensive debt, such as Term B Loan.
Notes: The Revolver Credit Facility is not expected to be drawn upon during the investment period.
2020E 2021E 2022E 2023E 2024E 2025E
Leverage Cover 4.7x 3.9x 3.2x 2.8x 2.2x 1.4x
Proposed (20% Headroom) 5.6x 4.7x 3.8x 3.3x 2.5x 1.6x
CAPEX Adjusted Leverage Cover 9.0x 6.1x 4.6x 4.0x 3.0x 1.8x
Proposed (20% Headroom) 12.0x 8.0x 6.1x 5.3x 4.1x 2.6x
Interest Cover 4.6x 6.0x 7.0x 8.4x 12.1x 21.1x
Proposed (20% Headroom) 3.7x 4.8x 5.6x 6.7x 9.7x 16.9x
CAPEX Adjusted Interest Cover 2.3x 3.6x 4.6x 5.5x 8.1x 14.9x
Proposed (20% Headroom) 1.8x 2.9x 3.7x 4.4x 6.5x 11.9x
Cash Cover 1.5x 3.2x 1.7x 1.3x 1.2x 1.5x
Proposed (Invariably) 1.0x 1.0x 1.0x 1.0x 1.0x 1.0x
Sources: Invesco Call; Team Assessment
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Returns – Breakdown – Returns to PE and MEP & Equity Bridge at Exit
After an exit in 2025, the PE is expected to return MOIC 3.5x and IRR 23.5%, while the investors in 
the MEP are looking at returns of MOIC 15.5x and IRR 57.9%
Returns to PE and MEP, In $mn
2020E 2021E 2022E 2023E 2024E 2025E
Initial PE Investment 647.0 647.0 647.0 647.0 647.0 647.0
Proceeds to PE 991.8 1,374.5 1,650.2 1,703.8 1,979.6 2,292.8
MOIC 1.5x 2.1x 2.6x 2.6x 3.1x 3.5x
IRR 53.3% 45.8% 36.6% 27.4% 25.1% 23.5%
Initial MEP Investment 20.9 20.9 20.9 20.9 20.9 20.9
Proceeds to MEP Investors 93.0 173.2 225.1 219.7 268.1 323.7
MOIC 4.5x 8.3x 10.8x 10.5x 12.8x 15.5x
IRR 345.3% 187.9% 120.9% 80.1% 66.6% 57.9%
• Over the projected 6-year investment period, the equity value is expected to increase by 3.9x,
from $668mn in 2020 to $2,616mn in 2025; the equity value creation throughout the investment
period arises from EBITDA growth – both from BioTel and the acquired SHL Telemedicine –,
multiple arbitrage and deleveraging.
• EBITDA growth for BioTel, which is the major contributor to the strong equity value with an
impact of $1,465mn, is driven by the significant growth in revenue as well as an improvement of
the company’s EBITDA margin.
• EBITDA growth for SHL Telemedicine had an impact of $112mn, which equals its EBITDA in
2025 considering that the company was acquired during the investment period, and hence did not
contribute in the beginning.
• Multiple arbitrage had an impact of $83mn, due to the difference of the SHL Telemedicine
acquisition multiple of 7.3x to the consolidation multiple of 12.7x.
• In total, the acquisition of SHL Telemedicine had an impact of $195mn.
• Deleveraging during the investment period had an impact of $308mn.
Equity Bridge at Exit in 2025E, In $mn
Sensitivity Analysis
• After an exit in 2025, the Institutional Investors, i.e. the PE fund, are expected to return $2,292.8mn
representing a money multiple of 3.5x and an IRR of 23.5%.
• Investors in the MEP, i.e. the management as well as the sales force, are expected to return
$323.7mn representing a money multiple of 15.5x and an IRR of 57.9%.
• These high returns are justified by higher volatility and provide an incentive for the investors to
work towards the same targets.











11.7x 26.7% 24.9% 23.3%
12.2x 25.8% 24.2% 22.6%
12.7x 25.1% 23.5% 22.0%
13.2x 24.4% 22.9% 21.4%
13.7x 23.8% 22.4% 20.9%











11.7x 3.3x 3.8x 4.3x
12.2x 3.2x 3.7x 4.2x
12.7x 3.1x 3.5x 4.0x
13.2x 3.0x 3.4x 3.9x
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Returns – Breakdown – Enterprise Value to Equity Bridge & Breakdown at Entry and Exit
Vast deleveraging during the investment period leaves much of the generated EV on the table for 
institutional investors and MEP participants
2 953 0
( 87) ( 33)
( 181) ( 35)
( 998)
1 618
EV Cash Term A Term B PIK Loan Other Debt FRI Ords















• Based on forecasted financials and returns, the exit is projected to occur in 2025. This results in an
investment period of 6 years.
• Based on the forecasted EBITDA of $232mn and an EBITDA multiple of 12.7x, which equals the
entry multiple, an expected Enterprise Value of $2,953mn can be generated in the sale of the
target company.
• Due to the full use of available cash for optional repayment of debt during the investment period,
there is no expected cash at hand.
• The debt of $87mn for Term A, $33mn for Term B, $181mn for the PIK Loan and $35mn for Other
Debt-like Items amounts to $336mn of total outstanding debt that will be repaid at exit.
• After the repayment of $998mn for the Fixed-Return Instrument, the remaining part of
$1,618mn will fall to the shareholders of the company.
• BioTel’s shareholder, i.e. institutional investors as well as the company’s management and sales
force through the Management Equity Program, will generate significant returns at exit.
• Post-acquisition in 2019, total equity amounts to $668mn, whereas at the projected exit, in
2025, total equity is expected to grow to $2,616mn.
• The Fixed-Return Instrument, senior to the shareholder’s ordinary shares, was initially installed at
acquisition with $563mn; at exit, the FRI is expected to amount to $998mn.
• Institutional Ords are expected to grow from $84mn (i.e. their value considering their share of
financing and transaction fees) to $1,295mn at exit, hence accounting for the largest part of the
company’s equity.
• MEP Ords are expected to grow from $21mn (i.e. their value considering their share of financing
and transaction fees) to $324mn at exit.
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BioTel’s scenarios assume EBITDA growth driven by a strong market, organic revenue growth 
measures as well as improvements in cost of revenue and other expenses
• The Upside Case anticipates a very strong organic growth,
driven by strong growth in BioTel Heart and the successful
market placement of the glucose monitor. Furthermore, it is
assumed, that reimbursement rates do not decrease for all
products, besides Extended Holter.
• Furthermore, cost savings from higher scaling effects are
reflected in cost of revenue and other expenses.











e • In the Downside Case an increase in sales is still assumed,driven by the promising market expectations and BioTel’s
historical performance.
• Due to non-successful cost measures, the cost of revenue is
assumed to increase significantly, resulting in a decrease in
EBITDA margin to 16.5% in 2025.
• Overall, EBITDA is assumed to increase at a modest CAGR of
1.0%.
21.4% 16.5%







• Strong growth in revenue, as well as cost saving measures,
result in a combined CAGR of 14.8%.
• Over 85% of revenue driven EBITDA growth results from organic
measures, such as the increasing sales force and the related
increase in patients.
• Due to scaling effects and cost-saving measures, significant
improvements in the cost of revenue and other expenses can be
realized.
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Exit & Due Diligence
Equity Story
Exit Strategies & Recommendation
Due Diligence
January 2020
Exit – Equity Story
BioTel is an attractive, diversified business, which is well positioned to create value under new 
ownership and beyond
BioTel – The #1 Telemedical Company
BioTel is an attractive, diversified business with three pillars: Remote Cardiac Monitoring, Clinical Trial Services and Health Population Management. Across all its activities, BioTel has developed into
the leading telemedical company, leveraging software and technology for the remote diagnosis and treatment of patients with cardiovascular health issues as well as chronic diseases, such as diabetes,
hypertension and sleep apnea.
The company’s clear value proposition lies within its offer of making health care accessible to anyone, anywhere while improving the quality, but reducing the cost for all – patients, physicians, and public
or private health care systems.
Market Leadership
BioTel is #1 in RCM, with all set to stay at the top
• RCM services are the major contributor to the vast revenue
growth driven by BioTel’s market-leading position; an
increased sales push over the investment period has led to an
expansion of BioTel’s market share in the US.
• This strong market position in the US favors the
geographical expansion to EMEA, which has already started
with the acquisitions of ADEA Medical and SHL Telemedicine.
Financial Success
BioTel’s revenue and EBITDA growth are skyrocketing
• BioTel, while of considerable size, has experienced enormous
growth over the investment period with an attractive revenue
CAGR of 11.9%, hereby outgrowing its major market for
Remote Cardiac Monitoring services.
• High EBITDA margins, paired with steady overhead, efficient
use of NWC and CAPEX, also provide for BioTel’s stable Cash
Flow, making the company highly leverageable.
Value Creation Potential
BioTel is on the way to become the next MedTech Star
• More than 2/3 of the revenue generated in 2025 stem from
the provision of software or high-tech solutions, which is
the result of the company’s strategic development towards the
leading provider of remote health care services, leveraging
software and technology, across different therapeutic areas1.
• This focus on high-value adding services in fast-growing
markets ensures a vast potential for further value creation.
Key Reasons For the Deal ValidationRationale
102 135 176 197 194 214 232
475 581
717 782 822 875
935
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• At this stage, the recommendation is to assess a strategic sale or an IPO.
• This is particularly driven by the large transaction deal size and the strong value proposition of BioTel, which positions the company
well towards strategic buyers looking for self-sustaining businesses as well as towards the market.
Exit – Strategies & Recommendation 
BioTel is well positioned for sale to strategic buyers or to go public in an IPO, particularly driven by 
its strong value proposition 
Sources: 1Bain, Global Healthcare Private Equity and Corporate M&A Report (2019); 2Private Equity Exit Strategies – IPOs, Trade Sales and Secondary Buyouts (2018)
Exit Decision Factors & Recommendation
Secondary Buyout Strategic Sale IPO
Secondary buyouts were the most common exit strategy in
Healthcare and MedTech deals in 2018, accounting for
approximately 47% and 40%, respectively1.
Sales to strategic corporate buyers were the 2nd most common
exit strategy in Healthcare deals in 2018, accounting for
roughly 40% of all exits1.
• Advantages: This strategy enables the PE firm to perform a
fast and complete exit; additionally, unlike in an IPO process,
the PE firm has full control over the timing of the process.
• Disadvantages: Selling to financial buyers typically generates
a lower premium than other exit strategies.
• Advantages: The advantages of a strategic sale are similar to
a secondary buyout, with the exception that realized synergies
increase the willingness to pay a higher acquisition premium.
• Disadvantages: Due to anti-trust regulation, the completion of
the deal is sometimes withdrawn or even cancelled2.
• Advantages: At favorable market conditions, the advantage of
an IPO is the potential premium that can be realized.
• Disadvantages: IPOs are characterized by higher uncertainty,
greater regulatory burden, transaction costs as well as the
cash-out restriction.
IPOs were the least common exit strategy in 2018, mainly
because their value fell 34% globally as market uncertainty and
higher volatility curtailed activity1.
BioTel is considered to be an attractive target for secondary
buyout due to its enormous potential for future value
creation, strong market-leading position and stable free
cash flow generation.
Given the large size of BioTel, large PE firms, such as the
Blackstone Group and KKR are considered to be potential
acquirers due to their ability to raise the required funds for





Given that all large US healthcare conglomerates, including
United Health Group, Medtronic and Abbott Laboratories, are
listed at the New York Stock Exchange, an IPO at the NYSE
should position the company to the right investors.
However, looking at recent IPOs of healthcare companies in the
US, there are two that are comparable: Castlight and Livongo
Corp; while the first one was carried out on the NYSE, the larger
valuation was achieved on NASDAQ.
Potential strategic buyers include all healthcare conglomerates,
such as the Boston Scientific Corporation, Abbott Laboratories or
Medtronic, considering the vast potential for synergies and
the technologically advanced product offering of BioTel.
Out of all healthcare conglomerates, two have been identified as
high-potential acquirers: Medtronic and Boston Scientific; both
are operating in the cardiac health space and showed interest
in growing their operations with large recent acquisitions.
• Transaction Deal Size (Expected EV of ~$2,952mn).
• Business Model, Synergies and Future Value Creation.
Exit Decision Factors Recommendation
Acquisition of BTG plc 
Deal size: $3,968mn, 2019
Deal Size:
$1,300mn
Acquisition of Cardinal Health 
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Due Diligence
Key DD areas that require further analysis are the evolution of reimbursement rates and 







Area Key Points Red Flags Importance
Reimbursement
• Further analysis on the reimbursement rates evolution in the RCM market.
• Evaluate the political risk on the Medicare services’ coverage and reimbursement.
• In-depth analysis of premium paid by commercial insurances over Medicare rates.
• No clear reimbursement rates forecast.
• Uncertainty when the transfer of the Extended Holter













• Evaluate the risk of substitution arising from possible better and more precise
cardiac monitoring devices and technology.
• In-depth analysis of entry barriers for large healthcare conglomerates.
• Different emerging startups identified with
promising technology.
• Unclear market players due to high fragmentation.
Market Size
• Evaluate assumptions for the number of accounts and the number of patients
per account.
• Further analysis of the different Cardiac Monitoring market segments’ growth rates.
• No clear data on the total number of accounts in the
Remote Cardiac Monitoring market.
• Unclear market growth rates per market segment.
Performance
• In-depth analysis of the current performance of the different monitoring devices.
• Analysis of recent BioTel’s asset write-downs and increase in DSO ratio.
• Further analysis on BioTel’s organic vs. inorganic growth drivers.
• No clear breakdowns of revenue contribution per
device nor market shares for each device.
• Unclear asset write-down of $12mn in 2018.
SHL Telemedicine 
Acquisition
• In-depth analysis of SHL’s assets and liabilities consolidation.
• Further evaluate cost-saving opportunities and operational improvements.
• Evaluate impacts on SHL’s customer relationships arising from the acquisition.
• Uncertainty on monitoring centers consolidation due
to language barriers and different cultures.
• Possible negative impact on SHL’s brand value.
Valuation
• Further evaluate the different valuation approaches’ assumptions.
• Analysis of possible multiple arbitrage opportunities, mainly related to SHL
acquisition and exit strategy.
• No direct trading comparable companies identified.
• Risk of having a misleading company valuation.
• Multiple arbitrage in acquisition of SHL was assumed.
European 
Regulation
• In-depth analysis of European regulation related issues with SHL acquisition.
• Further analyze the possibility of using BioTel’s cardiac devices in the European
market.
• Risk of long-lasting regulation settlements that
make the European expansion impossible.
Intellectual 
Property
• In-depth analysis of risks and threats arising from patents expiration, mainly in
revenue generation and market share.
• Evaluate current BioTel’s legal settlements related to patents violations.
• Risk of competitors copying BioTel’s key technology.
• Risk of further high legal costs and negative impact
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Appendix 1 – Precedent Transaction Sample
Sample for precedent transactions consists of four target companies with a median EBITDA margin 
of 18.1% and an effective EV/EBITA multiple of 12.9x








US-based provider of scientific-enabled 
Medical Imaging, eHealth, and patient-
centric solutions supporting clinical 
research
JLL Partners 13/03/2013 105 98 12 12.0% 1.1x 8.9x
Axis-Shield plc
UK based Anglo-Norwegian developer, 
manufacturer, marketer and seller of 
diagnostic tests for diagnostic and 
monitoring of human disease
Alere, Inc. 21/10/2011 401 159 23 14.2% 2.4x 16.9x
Somanetics Corp. US-based medical device manufacturer Covidien plc 28/07/2010 264 50 11 22.0% 5.3x 24.0x
HealthTronics, Inc.
US-based manufacturer of medical 
devices and provides repair services, 
with additional interest in clinical 
laboratory services
Endo International 
plc 15/07/2010 261 185 82 44.4% 1.4x 3.2x
Mean 23.1% 2.5x 13.3x
Median 18.1% 1.9x 12.9x
High 44.4% 5.3x 24.0x










Integer Holdings ICU Medical Natus Medical
Appendix 2 – Trading Comparable Companies Overview
Direct trading comparables identified are Medical Equipment manufacturers and Diagnostic 
Services providers with similarities to BioTel’s business model and financials
Business Model Overview
• Leading manufacturer and marketer of disposable medical
devices used in interventional, diagnostic and therapeutic
procedures, particularly in cardiology, radiology, oncology, critical
care, and endoscopy.
• Sells to hospitals and other healthcare providers that receive
reimbursement for the services provided to patients from third-
party payers, such as Government programs.
• Integer Holdings is one of the largest medical device outsource
manufacturers in the world serving the cardiac, neuromodulation,
vascular and portable medical markets.
• Medical customers include large multi-national medical device
OEMs and their subsidiaries.
• ICU Medical develops, manufactures and sells innovative medical
products used in infusion therapy and critical care applications.
• Primary customers are acute care hospitals, wholesalers,
ambulatory clinics and alternate site facilities
• The ability of customers to obtain appropriate reimbursement for
healthcare services and products from third-party payors is
critical.
• Leading provider of neurology, newborn care, and hearing and
balance assessment healthcare products and services used for
the screening, diagnosis, detection, treatment, monitoring and
tracking of common medical ailments in newborn care, hearing
impairment, neurological dysfunction and neurosurgical
treatments, epilepsy, sleep disorders, neuromuscular diseases,
and balance and mobility disorders.
Sources: Bloomberg; Trading Comparable Companies Annual Reports



































Diagnostic Equipment &ServicesMedical Equipment Manufacturer
Median:12.9x
Average:12.9x






Appendix 3 – Extrinsic Valuation Overview
Comparable trading companies operate in the Medical Equipment and Diagnostic Services sectors 
and TTC analysis indicates a median EV/EBITDA multiple of 13.6x
• The most similar trading companies are US-based firms, which operate in the Medical Equipment
and Diagnostic Services sectors. However, comparable companies are very limited.
• EV/EBITDA LTM multiples were retrieved for these companies and median and average multiples
were computed.
• This valuation approach implies an EV/EBITDA multiple range of 10.8x-13.2x, with a median
multiple of 12.4x, which leads to an EV range of $1.1-$1.3bn.
• The average EV/EBITDA LTM multiples for the period 2010-2019E were computed for all the
trading companies previously identified.
• Median and average values for the respective average multiples were determined.
• This valuation approach implies an EV/EBITDA multiple range of 15.6x-21.8x, with a median
multiple of 18.5x, which leads to an EV range of $1.6-$2.2bn, considering BioTel’s 2019 EBITDA
of $102mn.
• EV/EBITDA LTM Through the Cycle analysis was performed using the trading companies
previously identified.
• EV/EBITDA LTM multiples for the period 2015-2019E were used and their median and average
values were computed.
• This valuation approach implies an EV/EBITDA multiple range of 6.6x-31.1x, with a median
multiple of 13.6x, which leads to an EV range of $0.7-$3.2bn.
Trading Comparable 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Merit Medical Systems 12.1x 16.6x 11.1x 15.7x 15.2x 12.8x 13.7x 18.9x 27.9x 26.5x
Integer Holdings Corp 14.4x 6.6x 6.6x 10.4x 12.7x 11.8x 56.0x 13.0x 13.2x 13.8x
ICU Medical 7.7x 6.2x 5.6x 8.2x 9.3x 15.9x 16.6x 19.2x 78.7x 44.9x
NatusMedical 16.7x 14.1x n.a. 19.4x 14.5x 19.3x 21.8x 14.4x 34.3x n.a.
Median 13.3x 10.4x 6.6x 13.1x 13.6x 14.4x 19.2x 16.7x 31.1x 26.5x













EV/EBITDA LTM Through the Cycle EV/EBITDA LTM




















Sources: Bloomberg; Merger Market
Appendix 4 – Extrinsic Valuation Overview
Precedents transactions valuation include a sample with transactions in the period 2010 to 2013 
and recommend a median EV/EBITDA multiple of 16.9x
EV/EBITDA LTM vs. 5-Year Revenue CAGR Regression
• Regression analysis was done having the revenue CAGR for the past 5 years (2015-2019) as the independent variable and EV/EBITDA LTM multiple as the dependent variable.
• The sample used was the trading comparable companies previously identified.
• Revenue CAGR for the past 5 years were retrieved and the regression line was computed.





HealthTronics Somanetics Axis-Shield BioClinica
Median:12.9x
Average:13.3x
• Precedent transactions identified occurred between 2010-2013 in the Medical Equipment and
Diagnostic Services sectors, mostly in the US. Further detail on precedent transactions is available
in the next Page.
• This valuation approach implies an EV/EBITDA multiple range of 3.2x-24.0x, with a median
multiple of 12.9x, which leads to an EV range of $0.3-$2.4bn.
R² = 0.7019

















Trading Comparable 5-Year Revenue CAGR EV/EBITDA LTM
Merit Medical Systems, Inc. 13.5% 13.2x
Integer Holdings Corporation 12.1% 11.9x
ICU Medical, Inc. 31.8% 10.8x









Appendix 5 – DCF Analysis – Intrinsic Valuation
Based on a risk-adjusted WACC of 9.7% the DCF valuation suggests an Enterprise Value of 
$1,184mn or 11.6x LTM EBITDA
DCF
• DCF is based on BioTel’s stand-
alone financials. Hence, SHL
contribution is not included in
EBITDA, Tax, changes in NWC nor
CAPEX.
• PV Future Cash Flows and PV of
Terminal Value account for 44.6%
and 55.4% of total Enterprise Value,
respectively.
• Enterprise Value is $1.2bn, which
corresponds to a 11.6x multiple,
considering a WACC of 9.7% and
terminal revenue growth of 2.0% in
perpetuity.
WACC
• Risk-free rate and MRP are based
on Duff & Phelps recommendation
as of 2019.
• Unlevered beta is based on trading
comparable companies’ and it was
relevered with the industries’
average financial structure.
• Considering the levered beta of
1.15, the cost of equity is 9.8%.
• Based on BioTel’s annual report,
the firm’s cost of debt is 4.7%.
• WACC was adjusted by a risk
premium, due to the companies’
reimbursement risk and high growth
of future revenue.
Rationale
Weighted Average Cost of Capital
Risk-Free Interest Rate 3.50%
Market Risk Premium 5.50%




Levered Equity Beta 1.15
Cost of Equity 9.8%




Terminal Value Growth 2.0%
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In $mn Pro Forma E E E E E E E E E CAGR
12 Months Ending Dec-19 Dec-20 Dec-21 Dec-22 Dec-23 Dec-24 Dec-25 Dec-26 Dec-27 Dec-28 TV 2019-2025
EBITDA 101.8 135.3 164.0 183.3 178.4 196.1 213.4 226.2 239.9 250.9 13.1% 
(-) Statutory Tax Expense 10.5 16.5 24.5 25.2 23.4 27.1 30.6 33.0 35.2 36.9 19.6% 
Operating Cash Flow 91.3 118.8 139.6 158.1 155.0 169.0 182.8 193.2 204.7 214.0 12.3% 
(-) D in Net Working Capital 1.5 9.8 (3.4) 8.8 (10.9) 15.0 (9.6) 13.8 (9.2) 13.2 n.a.
(-) CAPEX 40.0 68.9 68.6 64.1 61.8 65.6 64.2 78.8 83.6 86.9 8.2% 
Investing Cash Flow 41.5 78.8 65.2 72.8 50.9 80.6 54.6 (92.6) (74.5) (100.1) 4.7%
Unlevered Free Cash Flow 49.8 40.1 74.3 85.3 104.1 88.3 128.2 100.6 130.2 113.9 1,508.6 17.0% 
Discount Factor 0.91 0.83 0.76 0.69 0.63 0.57 0.52 0.48 0.43 0.43
Present Value 36.5 61.8 64.6 71.9 55.6 73.5 52.6 62.1 49.5 655.6
Present Value of Cash Flows 528.1 44.6%
Present Value of Terminal Value 655.6 55.4%
Enterprise Value 1,183.7 11.6x
Net Debt 128.8 1.3x
Equity Value 1,054.9 10.4x





1.7% 1.8% 1.9% 2.0% 2.1% 2.2% 2.3%
8.2% 1,442.9 1,457.5 1,472.5 1,488.0 1,504.1 1,520.6 1,537.7
8.7% 1,334.0 1,346.1 1,358.6 1,371.4 1,384.6 1,398.2 1,412.3
9.2% 1,239.7 1,249.9 1,260.3 1,271.0 1,282.0 1,293.3 1,305.0
9.7% 1,157.2 1,165.8 1,174.6 1,183.7 1,193.0 1,202.5 1,212.3
10.2% 1,084.5 1,091.9 1,099.4 1,107.1 1,114.9 1,123.0 1,131.3
10.7% 1,019.9 1,026.2 1,032.7 1,039.3 1,046.0 1,052.9 1,060.0
11.2% 962.2 967.6 973.2 978.9 984.7 990.7 996.7





1.7% 1.8% 1.9% 2.0% 2.1% 2.2% 2.3%
8.2% 14.2x 14.3x 14.5x 14.6x 14.8x 14.9x 15.1x
8.7% 13.1x 13.2x 13.4x 13.5x 13.6x 13.7x 13.9x
9.2% 12.2x 12.3x 12.4x 12.5x 12.6x 12.7x 12.8x
9.7% 11.4x 11.5x 11.5x 11.6x 11.7x 11.8x 11.9x
10.2% 10.7x 10.7x 10.8x 10.9x 11.0x 11.0x 11.1x
10.7% 10.0x 10.1x 10.1x 10.2x 10.3x 10.3x 10.4x
11.2% 9.5x 9.5x 9.6x 9.6x 9.7x 9.7x 9.8x
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Appendix 6 – Maturity & Spreads
Interest rates are computed as 5-Year Libor Swap Rate plus the respective Loan’s spread
Debt Instrument Tenor(in Years) 2020 2021 2022 2023 2024 2025 2026 2027
5-Year Libor Swap Rate n.a. 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%
Spreads
Term A 7 4.0% 4.0% 4.0% 4.0% 4.0% 4.0% 4.0% n.a.
Term B 8 4.5% 4.5% 4.5% 4.5% 4.5% 4.5% 4.5% 4.5%
PIK Loan 10 8.5% 8.5% 8.5% 8.5% 8.5% 8.5% 8.5% 8.5%
RCF n.a. 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0%
Interest Rates
Term A 7 5.5% 5.5% 5.5% 5.5% 5.5% 5.5% 5.5% 5.5%
Term B 8 6.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0%
PIK Loan 10 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0% 10.0%
RCF n.a. 3.5% 3.5% 3.5% 3.5% 3.5% 3.5% 3.5% 3.5%
Average Interest Rate n.a. 6.3% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3% 6.3%
Sources: Bloomberg; Invesco Call
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Appendix 7 – Management Equity Program
The Management Equity Program is split between 19.6% to management team and the remaining 
80.4% to the sales force
Name Position # FTE Annual Salary (in $k)1
Salary
Ratio2 Investment Factor




Jospeh H. Capper CEO 1 635 100% 2 1,270 6.1%
Heather Getz CFO 1 394 100% 2 788 3.8%
Manish Wadwa CMO 1 336 100% 2 672 3.2%
Peter Ferola SVP, Legal 1 336 100% 2 672 3.2%
Andy Broadway SVP BioTel Heart 1 345 100% 2 689 3.3%
- Sales Force 120 70 100% 2 16,800 80.4%
Total Equity Investment of Management and Sales Force 20 891 100%
Notes: 1Salary ratio stands for the percentage of annual salary invested alongside the fund; 2Investment Factor stands for the multiple of annual salary invested. A 2-Factor multiple means 2x annual salary was invested.
Sources: BioTelemetry Proxy Statement
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